Eli Lilly stock surges after FDA approves obesity pill

The FDA approval of the oral obesity drug *Foundayo* acts as a potent fundamental catalyst, effectively confirming a bottoming process for LLY following its recent oversold condition. With the RSI at 22.97, the stock is technically primed for a mean reversion; the bullish MACD crossover suggests momentum is shifting from bearish exhaustion to aggressive accumulation. Given the recent $7.8B acquisition of Centessa and the InSilico partnership, Lilly is aggressively consolidating its R&D moat, which aligns with the robust revenue projections outlined in their recent 10-K filings. Traders should view this as a potential trend reversal setup: look for a breakout above the immediate resistance near $985 to confirm the move, utilizing the $935 level as a firm stop-loss to account for potential volatility within the $22.95 ATR range. Confluence between the positive news flow and extreme oversold technicals suggests a "buy-the-dip" opportunity, though investors should monitor the UK pricing dispute as a lingering risk that could temper institutional buying if headlines escalate.